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Invited Commentary 
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Recent studies have shown that the duodenum is a more 
COmmon site of primary gastrinomas than previously thought. It 
is CUrrently estimated that 30% to 50% of patients with sporadic 
Zollinger-Ellison Syndrome (ZES) have duodenal tumors [1-4]. 
l~urthermore, the majority of  multiple endocrine neoplasia type 
I (MEN:l) patients with ZES have one or more duodenal 
tumors with or without additional gastrinomas or other neuro- 
endocrine tumors [5-9]. It also may be surmised that the 
majority of patients who have been explored with biochemical 
evidence of ZES, but negative findings of  gastrinoma at explo- 
ration, have microgastrinomas of  the duodenum [10]. Finally, 
there is accumulating evidence that the " lymph node gastri- 
nOma" represents a metastasis from an occult duodenal pri- 
mary tumor which may still be present or previously removed 
and undetected after a partial or total gastrectomy [1,4, 11-13]. 
Thus, it is apparent that an awareness of  the frequency of 
dUOdenal gastrinomas and an ability to detect them at explora- 
tion is of critical importance in improving the cure rate of 
Patients with ZES who present without liver metastases. 
lmamura and colleagues found that only 21 of  114 patients 
Proven to have ZES in Japan from 1980 to 1991 had duodenal 
!3rimary tumors whereas 49 gastrinomas arose from the pan- 
Creas. However,  32 (28%) explorations for ZES were negative. 
!f most of these were microgastrinomas of  the duodenum, the 
InCidence of such tumors in potentially curable cases is nearly 
50%. 
Our experience during the past decade in exploring patients 
With ZES who had no apparent liver metastases, has shown that 
~ Plaroximately half of  them had either a duodenal gastrinoma or 
I Y.~Ph node metastasis [4, 8-10]. In those patients with only a 
ytnph node source of  gastrin found, a previous partial or total 
gastrectomy had been done. 
b'The authors observation that duodenal gastrinomas are less 
1°[o Ica omas of ancreahc origin is c g" Ily aggressive than gastrin p ' . " " ' 
onSlSte f other sur eons since the nt with those of a number o g 
original favorable results after surgical excision and long-term 
follow-up of a group of  11 patients reported by Oberheiman in 
1972 [14]. He concluded that patients with duodenal gastrino- 
mas, even with metastatic lymph node involvement, could be 
cured if the primary tumor and all metastatic nodes were 
removed. None of his surgically treated patients subsequently 
developed liver metastases. The present authors found that 
only 1 (9%) of  21 patients with a duodenal gastrinoma had liver 
metastases whereas 57% of those with pancreatic gastrinomas 
had liver involvement at the time of first presentation. The 
reported incidence of liver metastases in large series of  ZES 
patients in the United States has shown a progressive decline 
from 60% to around 20-30% during the past two decades [13, 
15, 16]. Whether this represents earlier diagnosis of the disease 
because of  the widespread availability and use of gastrin assays 
is not clear, but likely. The occurrence of liver metastases in 
our own patients with duodenal gastrinomas has been similar to 
the authors in that only one of 17 recent patients presented with 
a liver metastasis. Furthermore, that patient had only a single 
large (12 cm) metastasis in the right lobe. He underwent a right 
Iobectomy, excision of  the primary tumor plus 9 metastatic 
lymph nodes and after more than one year has maintained a 
normal basal and secretin stimulated gastrin level. Unlike the 
authors, we have not found any sporadic duodenal gastrinomas 
that were either multiple or in association with a concomitant 
pancreatic gastrinoma, nor have any similar cases been previ- 
ously reported (Kyoto, Cases i,2) [4-6]. Because these are 
common findings in MEN-I patients, one wonders whether 
these patients had a full endocrine evaluation for other compo- 
nents of  the syndrome. 
The treatment of  duodenal gastrinomas is controversial. In 
the authors personal experience with 7 patients in Kyoto,  6 
were treated by Whipple procedures with one death three 
months postoperatively from heart failure. In the total Japanese 
series, an additional 4 patients had Whipple procedures and 13 
patients had local excisions with or without gastrectomy. We 
have favored enucleation of tumors <0.5 cm in diameter and 
excision with a margin of  full thickness duodenal wall for larger 
neoplasms. In all cases, regional dissections of peripancreatic 
and hepatoduodenal lymph nodes is required because even 
tumors as small as !-2 mm have been associated with proven 
metastases [4, 9, 10]. More than 60% of our patients with 
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microgastrinomas have had proven lymph node metastases.  
With the exclusion of one patient with MEN-I ,  all o f  our 
patients treated during the past  10 years have normal gastrin 
levels and only one has required a " second  look"  procedure to 
excise an overlooked metastatic lymph node in the hepatoduo- 
denal ligament. Our results suggest that a more conservative 
approach can be successful in both sporadic and MEN-I pa- 
tients providing all involved nodes are excised as well as one or  
more primary tumors without incurring the potential morbidity 
and mortali ty of  a pancreatic duodenotomy.  
We are in agreement with the authors that the cellular origin 
of duodenal gastrinomas differs from that of  pancreatic gastri- 
nomas with resultant differences in both biological behavior  and 
immunohistological findings. None of 11 of our recently studied 
duodenal gastr inoma stained for either insulin or glucagon but 
all stained positive for gastrin. All of  them demonstrated mRNA 
for gastrin, chromogranin,  and neuronspecific enolase,  whereas 
none showed mRNA for proopiomelanocort in (POMC) or  
ACTH using in situ hybridization techniques. Both mRNA, 
POMC, and ACTH have been found in 30% of  our malignant 
pancreatic gastrinomas and their presence appears to be an 
indication of aggressive biological behavior [17]. 
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